Small Molecule Tyrosine Kinase Inhibitor Market Overview by Recent Opportunities, Growth Size, Regional Analysis and Forecasts to 2027

The global small molecule tyrosine kinase inhibitor market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Small molecule tyrosine kinase inhibitors (TKIs) block intracellular signalling pathways in tumor cells which leads to deregulation of key cell functions that include proliferation and differentiation. Additionally, as per the National Center for Biotechnology Information (NCBI), Small molecule inhibitors (SMIs) are among the most effective drugs for targeted cancer therapy. The major factor for the growth of the market is the increasing prevalence of cancer across the globe.

To Request a Sample of our Report on Small Molecule Tyrosine Kinase Inhibitor Market: https://www.omrglobal.com/request-sample/small-molecule-tyrosine-kinase-inhibitor-market

According to the National Cancer Institute (NCI), it was estimated that 1,806,590 new cases of cancer will be diagnosed in the US with a mortality rate of 606,520 people in 2020. Furthermore, there were 18.1 million new cases and 9.5 million cancer-related mortalities globally in 2018 which is anticipated to rise to 29.5 million and the number of cancer-related mortalities to 16.4 million by 2040. Hence, the rising prevalence of cancer is increasing the demand for small molecule tyrosine kinase inhibitors which in turn is driving the growth of the global small molecule tyrosine kinase inhibitor market.

Some major players in the market include Merck KGaA, Novartis International AG, and Pfizer Inc., among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in September 2020, Seattle Genetics has granted Merck an exclusive license to commercialize TUKYSA (tucatinib), a small molecule tyrosine kinase inhibitor in Asia, the Middle East and Latin America and other regions outside of the US, Canada and Europe. TUKYSA is used for the treatment of HER2-positive cancers

Market Coverage

• The market number available for - 2020-2027

• Base year- 2020

• Forecast period- 2021-2027

Segment Covered-

· By Type

· By Application

Regions Covered-

· North America

· Europe

· Asia-Pacific

· Rest of the World

Competitive Landscape- Merck KGaA, Novartis International AG, and Pfizer Inc., among others.

(Get 15% Discount on Buying this Report)

A full Report of Small Molecule Tyrosine Kinase Inhibitor Market is Available @ https://www.omrglobal.com/industry-reports/small-molecule-tyrosine-kinase-inhibitor-market

Global Small Molecule Tyrosine Kinase Inhibitor Market Report by Segment

By Type

• Phase-I

• Phase-I/II

• Phase-II

• Phase-II/III

• Phase-III

By Application

• Lung Cancer

• Breast Cancer

• Others

Global Small Molecule Tyrosine Kinase Inhibitor Market Report by Region

North America

· United States

· Canada

Europe

· UK

· Germany

· Spain

· France

· Italy

· Rest of Europe

Asia-Pacific

· India

· China

· Japan

· South Korea

· Rest of APAC

Rest of the World

· Latin America

· Middle East & Africa

Reasons to buy from us -

1. We cover more than 15 major industries, further segmented into more than 90 sectors.

2. More than 120 countries are for analysis.

3. Over 100+ paid data sources mined for investigation.

4. Our expert research analysts answer all your questions before and after purchasing your report.

Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404

About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

This release was published on openPR.